Project Grant R21DA064845
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $465,250 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award funds a double-blind, placebo-controlled human laboratory study investigating pregnenolone as a potential treatment for cannabis intoxication. The research will assess whether pregnenolone, which functions as a signaling-specific...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Icahn School of Medicine at Mount Sinai $507,000 on September 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct translational research on the epigenetic mechanisms underlying cannabis use disorder (CUD). The project, titled "Multiscale Insights into the Epigenetic Basis of THC Consumption," will operate through May 31, 2030, and focuses on developing preclinical models...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $647,142 to The University of Kentucky Research Foundation under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder (OUD). The project, initiated February 15, 2026 and concluding November 30, 2030, addresses a critical public health gap by providing the first controlled data on...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $248,201 Project Grant to the University of Colorado-Denver on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on cannabis detection methodologies. Over the two-year project period (ending March 31, 2028), the award funds rigorous validation of non-invasive, portable detection approaches for recent cannabis use, specifically breath sampling and pupil dynamics...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Columbia University's Health Sciences Division a $1.49M Project Grant (CFDA 93.279: Drug Use and Addiction Research Programs) beginning September 15, 2025, with completion targeted for May 31, 2030. This research initiative will conduct a longitudinal investigation of Veterans Health Administration (VHA) patient data to examine the relationship between cannabis use disorder (CUD) and opioid-related health outcomes....
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Washington $1,417,910 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the long-term neurobiological and behavioral effects of oral tetrahydrocannabinol (THC) consumption during adolescence. The project, which commenced July 1, 2025, and extends through March 31, 2030, delivers advanced neuroscience research services utilizing a validated THC-gelatin...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $1.9 million project grant, effective July 15, 2025 through March 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award supports basic neuroscience research investigating the neural basis of transitions from goal-directed to habitual behavior. The research employs a novel behavioral paradigm called "volitional engagement" to identify in...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $385,638 to The Regents of the University of Colorado (University of Colorado-Denver) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, with a completion date of August 31, 2028. This research award funds a three-year neurobehavioral investigation titled "Cannabinoid Tolerance Across Neurodevelopment: Disruption of Value-Driven Behavior and Prevention Through...
The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a $194,271 R21 Exploratory/Developmental Research Grant (CFDA 93.279: Drug Use and Addiction Research Programs) for the period May 1, 2026 through April 30, 2028. The project, "Optimizing Rodent Models of Drug Discrimination and Self-Administration of Vaporized Cannabis Extracts for Medications Development," will develop and validate preclinical rodent models to advance therapeutic research for Cannabis Use Disorder (CUD). The research addresses a critical gap in medication development by establishing reliable animal models that demonstrate the reinforcing effects of vaporized cannabis extract and its primary psychoactive component, delta-9-tetrahydrocannabinol (THC), through drug discrimination procedures and self-administration studies. The project deliverables include optimized rodent models utilizing inhalation-based vaporization technology to characterize the discriminative stimulus effects and reinforcing properties of cannabis/THC vapor. Aim 1 will establish vapor discrimination in rodents compared to intraperitoneally administered THC, including dose and time-course analyses, and identify optimal training doses for subsequent self-administration testing under second-order reinforcement schedules. These validated models are intended to facilitate the identification and testing of novel pharmacotherapies for CUD, for which no FDA-approved medications currently exist.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $194.3k | 4/28/26 |